Mecwins is pleased to announce that the Transfusion Centre of the Community of Madrid (CTCM) has formally approved our request to collaborate on supplying blood samples for the “Mecwins Sepsis Project: AVAC Sepsis Assay”. This approval, granted by the Centre’s Committee for Research and Teaching Evaluation, is a significant milestone in the development of our technology for the early detection of sepsis.
Having a stable and authorised source of biological samples is crucial for rigorously developing and validating high-sensitivity diagnostic assays. Through this collaboration, Mecwins will have access to a consistent supply of blood samples, enabling the generation of robust experimental data and supporting the progression of the AVAC Sepsis Assay towards more advanced research stages.
This agreement represents an operational benefit and an institutional endorsement of the scientific relevance and potential clinical impact of Mecwins’ work. It reinforces our commitment to delivering innovative diagnostic solutions aimed at improving the early detection of sepsis and patient management, one of the most critical challenges in modern healthcare.
Mecwins would like to express its gratitude to the Transfusion Centre for its support and trust. We look forward to a productive collaboration that will meaningfully contribute to the advancement of biomedical research and the development of next-generation diagnostic technologies.
